Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype.
Saved in:
| Title: | Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype. |
|---|---|
| Authors: | Páez, David1,2 dpaez@santpau.cat, Tobeña, María1, Fernández-Plana, Julen3, Sebio, Ana1, Virgili, Anna C.1,4, Cirera, Lluís3, Barnadas, Agustí1, Riera, Pau5,6, Sullivan, Ivana1, Salazar, Juliana2,5 |
| Source: | British Journal of Cancer. Jan2019, Vol. 120 Issue 2, p190-195. 6p. 1 Diagram, 5 Charts. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
